Roquefort Therapeutics
A UK-based biotech company developing first-in-class oncologicals prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently Oncogeni, which has developed two families of innovative cell and RNA oncology medicines.
Latest Roquefort Therapeutics News & Features
6 November 2023
1 July 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze